

## **REMARKS/ARGUMENTS**

Claims 1- 40 are pending in the present Application.

The Office has given a restriction requirement in the present action. In response, to the present Office action, Group 1, comprised of Claim 1, has been elected, without traverse.

Claims 2-40, which have not been elected in the present Office Action, have been withdrawn.

### **I. Restriction and Election under 35 U.S.C. 121**

#### **a. Restriction of Claims 1-40**

According to the August 9, 2006 Office Action, Claims 1-40, of Groups I-IX, are allegedly distinct, each from the other because of the following reasons:

**Group I.** Claim 1 drawn to a genetically modified, non-human mammal comprising an  $\alpha 2/\delta 1$  gene comprising 290-like mutation, classified in class 800, subclass 8.

**Group II.** Claims 2-9, drawn to a genetically modified, non-human mammal wherein the modification results in a mutated  $\alpha 2/\delta 2$  gene encoding polypeptide classified in class 800, subclass 8.

**Group III.** Claims 10, 11, 13-14, and 17-23 drawn to an isolated nucleic acid molecule and to a host cell comprising mutated  $\alpha 2/\delta 2$  gene encoding polypeptide, classified in class 435, subclass 320.1 and subclass 325.

**Group IV.** Claim 12 drawn to a genetically modified, non-human mammal comprising nucleic acid sequence set forth in SEQ ID NO: 39, classified in class 800, subclass 8.

**Group V.** Claim 15-16 drawn to a non-human mammal that is the progeny of a first and as second mammal wherein the first mammal is a genetically modified with mutation in  $\alpha 2/\delta 2$  gene and the second mammal is a genetically modified with mutation in  $\alpha 2/\delta 1$  gene classified in class 800, subclass 8.

**Group VI.** Claims 24-25 drawn to a method of identifying a gene that demonstrates modified expression profile in a cell with mutated  $\alpha 2/\delta 2$  gene, classified in class 435, subclass 375.

**Group VII.** Claims 26-27 drawn to a method of identifying a protein that demonstrates modified proteomic and/or post translational profile in a cell with mutated  $\alpha 2/\delta 2$  gene, classified in class 435, subclass 7.

**Group VIII.** Claim 28-29 drawn to a method of producing a transgenic animal, classified in class 800, subclass 21.

**Group IX.** Claim 30-40 drawn to a method of determining the physiological effect of compounds involving binding to  $\alpha 2/\delta 2$  polypeptide, classified in class 800, subclass 3.

**b. Election of a Single Group from Groups I-IX, without Traverse.**

In response to the restriction, Applicants elect Group I from Groups I - IX, without traverse.

Group I is comprised of Claim 1 drawn to a genetically modified, non-human mammal comprising an  $\alpha 2/\delta 1$  gene comprising 290-like mutation, classified in class 800, subclass 8.

Applicants reserve the right to rejoin process claims should the product claim be found allowable.

**c. Conclusion**

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, the Examiner is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,



Philip B. Polster, II  
Attorney for Applicants  
Reg. No. 43,864  
PHARMACIA CORPORATION  
Corporate Patent Law Department  
314-274-9094 (St. Louis)